Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

MORE ON PNSN

Even though PNSN is not being official held in the portfolio any longer, we will continue to provide information on PNSN at least for the time being. The key question is if the present price discounts the dilution.  The other key question is if there is more information that the company has not released. Here is a quote from the company’s response: Book value after dilution?  Under the plan, we would eliminate approximately $176 million of debt and $30 million of annual cash interest expense, increase equity at our parent company, and potentially realize a significant one-time gain as a

Read More »

MORE INFORMATION ON PNSN

The stop hit on PNSN and the position is no longer being held.  However, we recognize that some subscribers are still holding PNSN. We asked PNSN a number of questions and also requested them to verify the authenticity of the following letter: March 28, 2012Dear Valued Correspondent As you have no doubt noticed, the price of our common shares has declined over the last week. We believe this is due to the potential share dilution that is part of Penson Worldwide, Inc.’s recently announced debt exchange offer plan, and is a sign of confidence in the ultimate success of that

Read More »

NO QE3: GOLD, SILVER, BONDS GET CREAMED

At 11:26 a.m. today, I received an email from a well-known market guru who is an expert at technical analysis. The email declared that the pattern in gold was like a coil ready to start a new rally. At 2:00 p.m. the Federal Reserve Board and the Federal Open Market Committee (FOMC) released the minutes of the Committee meeting held on March 13, 2012. In response to the minutes, gold fell about $35, with silver, oil, bonds and stocks all falling as well. As of this writing, the SPDR Gold Trust ETF GLD -1.29% is down $3.25, iShares Silver Trust ETF SLV -3.01% is down $0.40,

Read More »

IT’S DEATH BY APPLE FOR BEST BUY

“Best Buy has simply become a show room for Amazon,” I wrote about two years ago. At that time, Best Buy stock was trading at $45. As of this writing, the stock is just above $24. After Best Buy (BBY) reported earnings on Thursday, there has been a barrage of negative articles on Best Buy and how Amazon.comis beating Best Buy.  There was a similar barrage after the earnings report in the previous quarter. Kudos to Forbes reporter Halah Touryalai for writing,“Amazon Is Not A Threat To Best Buy, Markets Overreacting, Analyst Says. ” It takes guts to write contrary to prevailing wisdom especially when the

Read More »

GOOGLE’S BRAND NEW CHALLENGE TO APPLE’S IPAD

The iPad has been a big success for Apple (AAPL). Apple bulls dream of iPad gaining and maintaining a market share similar to iPod. As a matter of fact, this is one of the propositions underlying some of the very high targets by analysts on Apple stock. Until now, there has been some justification for such a proposition. Tablets based on Google (GOOG) Android have not met with much success, even though Android phones are a huge success. Playbook from Research In Motion (RIMM) has been a flop. Kindle from Amazon (AMZN) and the Nook from Barnes & Noble (BKS)

Read More »

WEEKY MARKET DIGEST: INCREASE IN PERSONAL SPENDING 400% OF PERSONAL INCOME INCREASE

(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers.) INCREASE IN PERSONAL SPENDING 400% OF PERSONAL INCOME INCREASE March 30, 2012 February personal spending came at 0.8% and personal income came at 0.2%. In the short-term, in a consumer driven economy like the U.S., increase in personal spending is great for the stock market. However, in the long run, without commensurate increase in personal income, personal spending will fall off. This is a red flag. If personal spending increase continues to far exceed personal income

Read More »

APPLE INSIDERS DUMP STOCK

In the month of March, Apple (AAPL) insiders have been dumping their stock.  It is said a picture is worth a thousand words.  There is no picture here, so the table below will have to do.  I am purposely not regurgitating in one thousand words the contents of the table.  The words are better used to describe what this selling means.     Gauging sentiment is an important part of my investing method.  For the purpose of analysis, these days we gather sentiment data from individual investors in four classes in addition to the data from institutional investors. For an astute investor,

Read More »

FORGET LIPITOR, HERE COMES THE NEXT BIG THING

In 1971, a Japanese biochemist, Akira Endo, started work on what turned out to be the next big thing in the prevention of heart attacks and strokes, known as statins. In 1978, Merck (MRK) isolated lovastatin from fungusAspergillus terreus. Lovastatin is naturally contained in red yeast rice, a traditional Chinese fermented rice that is bright reddish purple in color.  Lovastatin was first marketed as Mevacor in 1987.  Merck started perhaps one of the most successful health related campaigns to convince the public and doctors of the dangers of high cholesterol and the effectiveness of statins to control it. Another statin, atorvastatin, marketed

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content